RF1MH133426
Project Grant
Overview
Grant Description
The impact of the COVID-19 pandemic on severe mental illness - Abstract
Many studies have shown the disproportionately high rates of SARS-CoV-2 infection and its medical complications, including death, experienced by individuals with pre-pandemic severe mental illness (SMI). By contrast, very few studies have thus far attempted to rigorously examine the impact of the pandemic, and infection specifically, on brain and behavioral function in this highly vulnerable group. The lack of such studies is a matter of growing public health concern, given evidence that, in the population overall, the pandemic has been associated with potentially long-lasting deteriorations in measures of mental health and cognitive performance.
This proposal is to fill major gaps in our knowledge base, regarding the impact of the COVID pandemic on individuals living with SMI – defined here to include schizophrenia, bipolar disorders, and severe major depressive disorders. We will do so through new studies that leverage existing, longstanding projects that have focused on elucidating causes and trajectories of SMI, in the Paisa population of Colombia.
To conduct these studies, we will re-engage and reassess the Paisa-Project participants whom we originally investigated pre-pandemic. Specifically, we will measure outcomes of the pandemic and potential predictors of those outcomes, in individuals with pre-existing SMI and controls (Aim 1). Among the outcome and predictor measures that we will obtain are: neurocognitive batteries, symptom scales, assessments of SMI-related dimensional traits (such as anhedonia) and of pandemic experiences, questionnaires on social determinants of health, SARS-CoV-2 serology, and whole exome and whole genome genotypes.
We will then (Aim 2) conduct analyses to identify the relationships between specific outcomes and predictors evaluated in Aim 1. Finally (Aim 3), we will use our EHR-linked biobank to evaluate the relationships in a larger, independent case/control sample, identify modifiers of these relationships, and develop models to predict pandemic-related suicide attempts and changes in healthcare utilization in individuals with SMI.
Many studies have shown the disproportionately high rates of SARS-CoV-2 infection and its medical complications, including death, experienced by individuals with pre-pandemic severe mental illness (SMI). By contrast, very few studies have thus far attempted to rigorously examine the impact of the pandemic, and infection specifically, on brain and behavioral function in this highly vulnerable group. The lack of such studies is a matter of growing public health concern, given evidence that, in the population overall, the pandemic has been associated with potentially long-lasting deteriorations in measures of mental health and cognitive performance.
This proposal is to fill major gaps in our knowledge base, regarding the impact of the COVID pandemic on individuals living with SMI – defined here to include schizophrenia, bipolar disorders, and severe major depressive disorders. We will do so through new studies that leverage existing, longstanding projects that have focused on elucidating causes and trajectories of SMI, in the Paisa population of Colombia.
To conduct these studies, we will re-engage and reassess the Paisa-Project participants whom we originally investigated pre-pandemic. Specifically, we will measure outcomes of the pandemic and potential predictors of those outcomes, in individuals with pre-existing SMI and controls (Aim 1). Among the outcome and predictor measures that we will obtain are: neurocognitive batteries, symptom scales, assessments of SMI-related dimensional traits (such as anhedonia) and of pandemic experiences, questionnaires on social determinants of health, SARS-CoV-2 serology, and whole exome and whole genome genotypes.
We will then (Aim 2) conduct analyses to identify the relationships between specific outcomes and predictors evaluated in Aim 1. Finally (Aim 3), we will use our EHR-linked biobank to evaluate the relationships in a larger, independent case/control sample, identify modifiers of these relationships, and develop models to predict pandemic-related suicide attempts and changes in healthcare utilization in individuals with SMI.
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
California
United States
Geographic Scope
State-Wide
Los Angeles University Of California was awarded
COVID-19 Impact on SMI: Brain & Behavioral Function
Project Grant RF1MH133426
worth $3,072,053
from the National Institute of Mental Health in April 2023 with work to be completed primarily in California United States.
The grant
has a duration of 3 years and
was awarded through assistance program 93.242 Mental Health Research Grants.
The Project Grant was awarded through grant opportunity Urgent Award: COVID-19 Mental Health Research (R01 Clinical Trial Optional).
Status
(Ongoing)
Last Modified 4/20/23
Period of Performance
4/15/23
Start Date
4/14/26
End Date
Funding Split
$3.1M
Federal Obligation
$0.0
Non-Federal Obligation
$3.1M
Total Obligated
Activity Timeline
Subgrant Awards
Disclosed subgrants for RF1MH133426
Additional Detail
Award ID FAIN
RF1MH133426
SAI Number
RF1MH133426-1505395331
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Public/State Controlled Institution Of Higher Education
Awarding Office
75N700 NIH NATIONAL INSTITUTE OF MENTAL HEALTH
Funding Office
75N700 NIH NATIONAL INSTITUTE OF MENTAL HEALTH
Awardee UEI
RN64EPNH8JC6
Awardee CAGE
4B557
Performance District
33
Senators
Dianne Feinstein
Alejandro Padilla
Alejandro Padilla
Representative
Pete Aguilar
Budget Funding
| Federal Account | Budget Subfunction | Object Class | Total | Percentage |
|---|---|---|---|---|
| National Institute of Mental Health, National Institutes of Health, Health and Human Services (075-0892) | Health research and training | Grants, subsidies, and contributions (41.0) | $3,072,053 | 100% |
Modified: 4/20/23